Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RG-012 in Alport Syndrome
NCT03373786Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lademirsen in Alport syndrome (2 arms), sponsored by Sanofi. Primary endpoints: Safety - Adverse Events at 8 weeks and Effect of RG-012 on renal microRNA-21 at 8 weeks. Started Dec 2017; status: completed.
02
Drugs
lademirsen
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT03373786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373786.